First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

On a cross-country road trip, a stop at a fast-food eatery is convenient and budget-friendly, but you should try to avoid ...

Dynavax Technologies Corporation , a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, and Vaxart, Inc. , a clinical-stage biotechnology company developing ...

Q3 2025 Earnings Call Transcript November 6, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-0.51282, expectations were $-2.15. Operator: Good day, and thank you for standing by.

Grocery shopping was once so straightforward pick up what you want and go home. But with today’s globalized food supply chain ...

This recall was a major health warning that many people missed. In late 2023, Salm Partners recalled over 130,000 pounds of ...

Boo! This week I’m revisiting “rambling mode” in my column – meaning my thoughts are swirling like the falling leaves and will not rake up nicely into a single theme. So here we go! I love being in ...

Neal J. Riley is a digital producer for CBS Boston. He has been with WBZ-TV since 2014. His work has appeared in The Boston Globe and The San Francisco Chronicle. Neal is a graduate of Boston ...

The FDA has adjusted the label of Johnson & Johnson and Legend Biotech’s Carvykti, warning patients and doctors that use of the multiple myeloma treatment could increase the risk of an intestinal ...